Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer

    Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug
                       Discovery Agreement with Pfizer

PR Newswire

BETHESDA, Md., Nov. 19, 2012

BETHESDA, Md., Nov. 19, 2012 /PRNewswire-USNewswire/ -- Cystic Fibrosis
Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and
development affiliate of the Cystic Fibrosis Foundation, today announced a
major expansion of its research collaboration with Pfizer Inc. designed to
discover new drugs to treat people with the most common mutation of CF, Delta
F508.

Under the new six-year pre-clinical research program with Pfizer, CFFT will
invest up to $58 million to speed the discovery and development of potential
therapies that target the underlying cause of cystic fibrosis.The program's
goal is to advance one or more drug candidates into the clinic by the end of
the multiyear collaboration.

"We are excited to expand our efforts with Pfizer to accelerate the
development of more therapies that treat the root cause of CF and benefit the
greatest number of people with the disease," said Robert J. Beall, Ph.D.,
president and CEO of the CF Foundation. "Pfizer brings impressive technical
and scientific expertise, along with its commitment to improving the lives of
people with cystic fibrosis."

In people with the Delta F508 mutation, a defective protein called CFTR does
not fold correctly and is unable to reach the cell surface, where it is needed
to help maintain the proper flow of salt and fluids into the airways. As a
result, thick secretions form in the airways, leading to serious lung
infections and lung damage. Nearly 90 percent of people with CF have at least
one copy of the Delta F508 mutation.

The collaboration will focus on identifying therapies that help restore normal
function of the defective protein. Pfizer researchers will draw on their
leading expertise in developing therapies that help mutated proteins fold and
route correctly within the cell.

"Innovative collaborations between industry and patient organizations are
increasingly critical in expediting the translation of science into new
treatments," said Jose-Carlos Gutierrez-Ramos, senior vice president of Pfizer
BioTherapeutics R&D. "We look forward to continued collaboration with the CF
Foundation and to applying our leading science with the goal of identifying
novel therapies for the treatment of this devastating disease."

This new agreement builds on CFFT's existing collaboration with Pfizer, which
began in 2010 when Pfizeracquired the biotech company FoldRx Pharmaceuticals
Inc., as part of the company's expanded effort to discover and develop
innovative medicines for rare diseases. The acquisition included FoldRx's CF
researchprogram in collaboration with CFFT which started in 2007. Pfizer
takes a collaborative approach to rare disease development and is partnering
extensively with stakeholders throughout the community to significantly
improve the lives of patients.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure
for cystic fibrosis. The Foundation funds more CF research than any other
organization, and nearly every CF drug available today was made possible
because of Foundation support. Based in Bethesda, Md., the Foundation also
supports and accredits a national care center network that has been recognized
by the National Institutes of Health as a model of care for a chronic disease.
The CF Foundation is a donor-supported nonprofit organization. For more
information, go to www.cff.org.

SOURCE Cystic Fibrosis Foundation

Website: http://www.cff.org
Contact: Laurie Fink, National Director, Media Relations, Cystic Fibrosis
Foundation, +1-301-841-2602; lfink@cff.org; Lauren Starr, Director, Media
Relations, Pfizer, +1-212-733- 3221, lauren.starr@pfizer.com